Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 8/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359007 | 0.92 | GPR139 (0.52) | GPR139ALDH1A1GAAKDM4EGLA | |
| SCHEMBL31359031 | 0.87 | GPR139 (0.48) | GPR139CA12CA9ALDH1A1GAA | |
| SCHEMBL31160993 | 0.86 | GPR139 (0.51) | GPR139ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL31359091 | 0.86 | GPR139 (0.51) | GPR139ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL31359130 | 0.86 | GPR139 (0.51) | GPR139ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL31358999 | 0.86 | GPR139 (0.52) | GPR139 | |
| SCHEMBL31359054 | 0.85 | GPR139 (0.47) | GPR139ALDH1A1GAAKDM4EGLA | |
| SCHEMBL31359110 | 0.83 | GPR139 (0.51) | GPR139 | |
| SCHEMBL31359099 | 0.82 | GPR139 (0.55) | GPR139ALDH1A1HPGDPOLB | |
| SCHEMBL31160829 | 0.81 | GPR139 (0.48) | GPR139CA12CA9ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | GPR139 4045/4885CA12 4840/4885CA9 4375/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | GPR139 3566/4885CA12 4671/4885CA9 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.